Brigham and Women's Hospital
Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus daratumumab-based regimens versus non-daratumumab based-regimens.
Objective 1: We will collect data from patients treated with plasma exchange from major centers across the United States to investigate whether plasma exchange improves renal outcomes. Specifically, we will collect data on at least 150 patients treated with plasma exchange along with 300 control patients not treated with plasma exchange. Objective 2: We will compare renal outcomes among patients with light chain cast nephropathy and AKI treated with plasma exchange (n=150) versus daratumumab based regimen (eg Dara-CyborD) (n=150) versus other novel regimens (e.g., CyborD or another non-dar…
Inclusion Criteria for Plasma Exchange-Treated Patients: 1. Adult (≥18 years old) 2. Either a new diagnosis of multiple myeloma confirmed by bone marrow plasmayctosis \>10% or acute relapse of multiple myeloma 3. Light chain cast nephropathy, with involved light chain \>500 mg/L 4. Acute kidney injury, defined as ≥1.5-fold rise in SCr from baseline (as defined in study outcomes) or the need for renal replacement therapy (RRT). 5. Treated with at least 1 round of plasma exchange within 30 days of diagnosis of cast nephropathy 6. Treated with plasma exchange in 2010 or later Inclusion Criteria…
Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
Arctuva estimate
Verify or correct the compensation shown for this listing.